Amedisys (NASDAQ:AMED) Price Target Cut to $180.00

Amedisys (NASDAQ:AMEDGet Rating) had its price objective lowered by investment analysts at Raymond James from $200.00 to $180.00 in a research note issued on Friday, The Fly reports. Raymond James’ price target suggests a potential upside of 36.48% from the stock’s current price.

Other equities analysts have also issued research reports about the company. UBS Group upgraded Amedisys from a “sell” rating to a “neutral” rating and raised their price target for the company from $152.00 to $168.00 in a research note on Tuesday, March 1st. Benchmark cut their price target on Amedisys from $200.00 to $175.00 and set a “buy” rating on the stock in a research note on Thursday, February 24th. Truist Financial cut their price target on Amedisys from $210.00 to $200.00 and set a “buy” rating on the stock in a research note on Friday, February 25th. BMO Capital Markets upgraded Amedisys from a “market perform” rating to an “outperform” rating and cut their price target for the company from $210.00 to $190.00 in a research note on Friday, February 25th. Finally, SVB Leerink raised their price target on Amedisys from $145.00 to $147.00 and gave the company a “market perform” rating in a research note on Friday, February 18th. Seven equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $191.06.

NASDAQ:AMED opened at $131.89 on Friday. Amedisys has a twelve month low of $122.12 and a twelve month high of $292.97. The company has a market cap of $4.29 billion, a price-to-earnings ratio of 20.80, a price-to-earnings-growth ratio of 2.46 and a beta of 0.72. The stock has a fifty day simple moving average of $156.26 and a 200-day simple moving average of $154.20. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 0.44.

Amedisys (NASDAQ:AMEDGet Rating) last released its earnings results on Wednesday, April 27th. The health services provider reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.11. Amedisys had a return on equity of 21.84% and a net margin of 9.44%. During the same quarter in the prior year, the business earned $1.54 earnings per share. As a group, equities research analysts predict that Amedisys will post 5.31 EPS for the current fiscal year.

In other news, insider David L. Kemmerly sold 2,500 shares of the business’s stock in a transaction dated Tuesday, March 29th. The stock was sold at an average price of $177.31, for a total transaction of $443,275.00. Following the sale, the insider now owns 16,336 shares in the company, valued at $2,896,536.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.80% of the stock is currently owned by insiders.

Several hedge funds have recently modified their holdings of the company. Covestor Ltd acquired a new stake in shares of Amedisys during the fourth quarter worth about $28,000. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Amedisys by 55.3% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 233 shares of the health services provider’s stock worth $38,000 after purchasing an additional 83 shares during the period. Allworth Financial LP acquired a new stake in shares of Amedisys during the first quarter worth about $38,000. Zullo Investment Group Inc. acquired a new stake in shares of Amedisys during the fourth quarter worth about $40,000. Finally, Confluence Wealth Services Inc. acquired a new stake in shares of Amedisys during the fourth quarter worth about $42,000. Institutional investors and hedge funds own 92.18% of the company’s stock.

About Amedisys (Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Featured Articles

The Fly logo

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.